Pharmaceuticals

Monogenetic Disease Therapy Market Future Outlook: Strong Growth Expected Toward $45.58 Billion by 2030

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the monogenetic disease therapy market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Monogenetic Disease Therapy Market in 2026, and what figure is it projected to hit by 2030?

The monogenetic disease therapy market has demonstrated significant growth in recent times. This market is projected to expand from $28.3 billion in 2025 to $31.08 billion in 2026, showing a compound annual growth rate (CAGR) of 9.8%. Factors contributing to its historical growth include progress in human genome research, the commencement of early gene therapy trials, an upsurge in rare disease diagnoses, the availability of orphan drug incentives, and innovations in viral vectors.

The monogenetic disease therapy market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $45.58 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This projected growth during the forecast period is attributable to several factors, including the advancement of gene editing platforms, an increase in rare disease pipelines, elevated genetic screening rates, enhanced funding for personalized therapies, and more widespread regulatory approvals. Key trends expected during this period encompass therapies targeting single genes, initiatives for gene replacement treatments, RNA-based genetic interventions, correction of rare disease genes, and the design of precision genetic drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33229&type=smp

Which Drivers Are Affecting Market Participation In The Monogenetic Disease Therapy Market?

The increasing acceptance of precision and personalized medicine is anticipated to propel the expansion of the monogenetic disease therapy market moving forward. This medical approach involves customizing disease prevention, diagnosis, and treatment based on an individual’s unique genetic, molecular, or lifestyle characteristics to optimize therapeutic efficacy and minimize adverse effects. The growth of precision and personalized medicine arises from healthcare providers and patients seeking tailored treatments that enhance therapeutic efficacy, reduce adverse reactions, and address individual genetic, molecular, or lifestyle profiles. Monogenetic disease therapy complements precision and personalized medicine by targeting a patient’s specific genetic mutation, thereby enabling highly individualized and effective treatments. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, stated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Thus, the growing adoption of precision and personalized medicine is fueling the development of the monogenetic disease therapy market.

What Segment Categories Are Covered In The Monogenetic Disease Therapy Market?

The monogenetic disease therapy market covered in this report is segmented –

1) By Therapy Type: Pharmacological; Surgical; Blood Transfusion; Gene Therapies; Other Therapy Types

2) By Inheritance Pattern: Autosomal; Chromosomal

3) By Application: Cystic Fibrosis; Sickle Cell Anemia; Phenylketonuria; Other Applications

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

5) By End-Users: Clinics; Hospitals; Diagnostic Centres; Home Healthcare; Other End-Users

Subsegments:

1) By Pharmacological: Small Molecule Drugs; Enzyme Replacement Therapies; Protein Replacement Therapies; Immunomodulatory Drugs; Targeted Molecular Therapies

2) By Surgical: Organ Transplant Procedures; Tissue Repair Surgeries; Gene Editing Assisted Surgeries; Minimally Invasive Surgeries; Corrective Surgical Interventions

3) By Blood Transfusion: Red Blood Cell Transfusions; Platelet Transfusions; Plasma Transfusions; Stem Cell Infusions; Autologous Blood Transfusions

4) By Gene Therapies: Ex Vivo Gene Therapy; In Vivo Gene Therapy; Viral Vector Based Gene Therapy; Non Viral Vector Gene Therapy; Genome Editing Based Therapy

5) By Other Therapy Types: Cell Based Therapies; RNA Based Therapies; Protein Based Therapies; Combination Therapies; Experimental Therapies

How Are New Market Trends Shaping The Landscape Of The Monogenetic Disease Therapy Market?

Leading companies within the monogenetic disease therapy market are concentrating on creating innovative gene therapies, including Duchenne muscular dystrophy (DMD)-targeted protocols, to slow disease progression and improve patient outcomes over the long term. Duchenne muscular dystrophy–targeted protocols represent structured clinical or therapeutic guidelines specifically designed to diagnose, monitor, and manage patients with Duchenne muscular dystrophy, focusing on decelerating disease advancement, enhancing muscle function, and addressing associated complications. For example, in January 2026, Sarepta Therapeutics Inc, a US-based biopharmaceutical company, launched Elevidys for ambulatory Duchenne muscular dystrophy (DMD) patients aged four and older. The company reported up to a 73% reduction in the rate of functional decline over three years compared with an external control group, underscoring the importance of early intervention to alter the disease course and improve quality of life.

Which Key Market Players Are Investing In Expansion And Innovation Within The Monogenetic Disease Therapy Market?

Major companies operating in the monogenetic disease therapy market are Pfizer Inc., Sanofi S.A., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics Inc., Ptc therapeutics inc., Crispr therapeutics ag, CRISPR Therapeutics, Voyager Therapeutics Inc., Oxford Biomedica plc, REGENXBIO INC., Arcturus therapeutics holdings inc., Editas medicine Inc., American Gene Technologies, UniQure NV., MeiraGTx Limited, Prime medicine, Abeona therapeutics Inc., Blue Cross Blue Shield Association, Rocket pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/monogenetic-disease-therapy-market-report

Which Regions Are Poised For Strategic Growth In The Monogenetic Disease Therapy Market?

North America was the largest region in the monogenetic disease therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monogenetic disease therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Monogenetic Disease Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33229&type=smp

Browse Through More Reports Similar to the Global Monogenetic Disease Therapy Market 2026, By The Business Research Company

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795